Vidyya Medical News Servicesm
Vidyya, from the Sanskrit "vaidya," a practitioner who has come to understand the science of life.

Volume 1 Published - 14:00 UTC    08:00 EST    02-October-2000      
Issue 172 Next Update - 14:00 UTC 08:00 EST    03-October-2000      

Vidyya Home  Vidyya

Home Of Our Sponsor, Vidyya.  Vidyya. Home

Vidyya Archives  Vidyya Archives

Search Vidyya  Search Vidyya

Visit Our Library  Ex Libris

Subscribe To Our News Service  Subscriptions

All About Us  About Vidyya



















Back To Vidyya Today In Vidyyasm

Vidyya Medical News Service For 02-October-2000:

The US Food and Drug Administration (FDA) has granted Serono, Inc. marketing approval for Ovidrel® (choriogonadotropin alfa for injection) for use in infertility treatment, making it the first recombinant human chorionic gonadotropin (hCG) to be approved in the world. The new drug can be injected subcutaneously, rather than intramuscularly, making it more convenient for women to administer.

In research news, the fight against multiple sclerosis (MS) received a set back this week when two trials studying a promising new treatment for MS were halted. Patients in the trials were experiencing two different types of adverse events--some patients were experiencing a worsening of MS symptoms while others were experiencing hypersensitivity reactions. We have information on the trials and a very in-depth look at MS from the NIH in today's Vidyya.

In a surprise announcement, researchers have found that fewer women with early-stage breast cancer are receiving appropriate primary therapy today than a decade ago, according to an analysis of national data collected by the National Institutes of Health (NIH). The problems stem from inappropriate procedures followed after lumpectomy.

And finally, a report in the 25 September issue of the Archives of Internal Medicine says that angiotensin-converting enzyme (ACE) inhibitors safely reduce mortality after myocardial infarction in patients with moderate renal insufficiency. Until this study, patients with renal insufficiency were excluded from efficacy trials for ACE inhibitors in post-MI patients.

The articles in today's Vidyya are:

As always, we hope you enjoy the issue.

Vidyya. Home |  Ex Libris |  Vidyya  | 
Subscription Information |  About Vidyya |  Vidyya Archives | 

Editor: Susan K. Boyer, RN
© Vidyya. All rights reserved.